Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Treatment, By End-use, By Region, And Segment Forecasts, 2023

The global ovarian cancer drugs market size is expected to reach USD 5.65 billion by 2030, registering a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Ovarian Cancer Drugs Market Report Highlights:

Based on treatment, the hospital pharmacy segment held the largest revenue share of 45.37% in 2022. An increasing number of government initiatives and funding for cancer research and treatment are driving drug development and accessibility, ensuring that effective ovarian cancer drugs are available in hospital settings. Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
For instance, in 2020, according to the Commonwealth of Australia, the Australian Government allocated USD 16.2 million toward eight research projects dedicated to addressing ovarian cancer. In Australia or globally, ovarian cancer has consistently maintained the lowest survival rate among all female cancers. On average, 43 out of every 100 women diagnosed with ovarian cancer survived five years after their diagnosis.
The online pharmacy segment is expected to grow at the fastest CAGR of 8.1% over the forecast period. The convenience of online pharmacies in facilitating the ordering and delivery of ovarian cancer drugs directly to patients' homes, particularly those with health limitations, is a significant driver of the online pharmacy segment in the ovarian cancer drugs treatment market. This accessibility eliminates barriers to obtaining essential medications, enhancing patient adherence to treatment regimens and expanding the market reach for these drugs.
For instance, AdooQ BioScience provides a convenient platform for customers to order ovarian cancer drugs, specifically Rucaparib. On the webpage, customers can access detailed information about the drug, including its name, description, dosage forms, and pricing.
North America dominated the industry with a market share of 43.47% in 2022 due to various factors, such as the high incidence of ovarian cancer in North America is a key driver of the region's ovarian cancer drugs market as it results in a significant and ongoing demand for effective treatments, fostering pharmaceutical research, and innovation to cater to the needs of the substantial patient population.
For instance, according to the American Cancer Society's 2023 estimates for ovarian cancer in the United States, approximately 19,710 women are expected to be newly diagnosed, while approximately 13,270 women are projected to lose their lives to ovarian cancer. *
Asia Pacific is expected to witness the fastest CAGR of 8.0% over the forecast period due to the increased participation in clinical trials in the region not only provides ovarian cancer patients with access to cutting-edge treatments but also fosters drug development by attracting pharmaceutical companies and researchers, thereby advancing the ovarian cancer drugs market in the region. *
For instance, according to the Clinical Trials Arena, from 2017 to 2022, Asia Pacific experienced an impressive increase of approximately 10% in clinical trials, surpassing the growth rate observed in other major regions like the U.S. and Europe. This growth in the region significantly outpaced the overall average of 5.3% per year during the same period.

Product Code: GVR-2-68038-380-5

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Therapeutic Class
- 1.1.2. Treatment
- 1.1.3. End-use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Therapeutic class outlook
- 2.2.2. Treatment outlook
- 2.2.3. End-use outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Ovarian Cancer Drugs Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Ovarian Cancer Drugs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Ovarian Cancer Drugs: Therapeutic Class Estimates & Trend Analysis

4.1. Ovarian Cancer Drugs Market: Key Takeaways
4.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. PARP Inhibitors
- 4.3.1. PARP inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Angiogenesis inhibitors
- 4.4.1. Angiogenesis inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. PD-L1 inhibitors
- 4.5.1. PD-L1 inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Ovarian Cancer Drugs: End-use Estimates & Trend Analysis

5.1. Ovarian Cancer Drugs Market: Key Takeaways
5.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Hospital Pharmacy
- 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Retail pharmacy
- 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Online Pharmacy
- 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Ovarian Cancer Drugs: Treatment Estimates & Trend Analysis

6.1. Ovarian Cancer Drugs Market: Key Takeaways
6.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Chemotherapy
- 6.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Radiation Therapy
- 6.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Hormonal Therapy
- 6.5.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Targeted Therapy & others
- 6.6.1. Targeted therapy & others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Ovarian Cancer Drugs Market: Regional Estimates & Trend Analysis

7.1. Regional Outlook
7.2. Ovarian Cancer Drugs Market by Region: Key Takeaway
7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
  - 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Sweden
  - 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Norway
  - 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
  - 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
  - 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
  - 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
  - 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
  - 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7. MEA
- 7.7.1. Saudi Arabia
  - 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. South Africa
  - 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
- 8.2.1. AbbVie Inc.
  - 8.2.1.1. Company overview
  - 8.2.1.2. Financial performance
  - 8.2.1.3. Product benchmarking
  - 8.2.1.4. Strategic initiatives
- 8.2.2. Pfizer, Inc.,
  - 8.2.2.1. Company overview
  - 8.2.2.2. Financial performance
  - 8.2.2.3. Product benchmarking
  - 8.2.2.4. Strategic initiatives
- 8.2.3. AstraZeneca,
  - 8.2.3.1. Company overview
  - 8.2.3.2. Financial performance
  - 8.2.3.3. Product benchmarking
  - 8.2.3.4. Strategic initiatives
- 8.2.4. F. Hoffmann-La Roche AG,
  - 8.2.4.1. Company overview
  - 8.2.4.2. Financial performance
  - 8.2.4.3. Product benchmarking
  - 8.2.4.4. Strategic initiatives
- 8.2.5. Johnson & Johnson Services, Inc.,
  - 8.2.5.1. Company overview
  - 8.2.5.2. Financial performance
  - 8.2.5.3. Product benchmarking
  - 8.2.5.4. Strategic initiatives
- 8.2.6. Boehringer Ingelheim International GmbH,
  - 8.2.6.1. Company overview
  - 8.2.6.2. Financial performance
  - 8.2.6.3. Product benchmarking
  - 8.2.6.4. Strategic initiatives
- 8.2.7. Clovis Oncology,
  - 8.2.7.1. Company overview
  - 8.2.7.2. Financial performance
  - 8.2.7.3. Product benchmarking
  - 8.2.7.4. Strategic initiatives
- 8.2.8. ImmunoGen, Inc.
  - 8.2.8.1. Company overview
  - 8.2.8.2. Financial performance
  - 8.2.8.3. Product benchmarking
  - 8.2.8.4. Strategic initiatives
- 8.2.9. Vivesto AB
  - 8.2.9.1. Company overview
  - 8.2.9.2. Financial performance
  - 8.2.9.3. Product benchmarking
  - 8.2.9.4. Strategic initiatives

Product Code: GVR-2-68038-380-5

List of Tables

Table 1 List of Abbreviations
Table 2 North America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 3 North America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 4 North America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 5 North America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 7 U.S. ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 8 U.S. ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 9 Canada ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 10 Canada ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 11 Canada ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 12 Europe ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 13 Europe ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 14 Europe ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 15 Europe ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 16 Germany ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 17 Germany ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 18 Germany ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 19 UK ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 20 UK ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 21 UK ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 22 France ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 23 France ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 24 France ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 25 Italy ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 26 Italy ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 27 Italy ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 28 Spain ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 29 Spain ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 30 Spain ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 31 Sweden ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 32 Sweden ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 33 Sweden ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 34 Norway ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 35 Norway ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 36 Norway ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 37 Denmark ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 38 Denmark ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 39 Denmark ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 40 Asia Pacific ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 41 Asia Pacific ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 42 Asia Pacific ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 44 China ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 45 China ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 46 China ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 47 Japan ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 48 Japan ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 49 Japan ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 50 India ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 51 India ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 52 India ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 53 Thailand ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 54 Thailand ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 55 Thailand ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 56 South Korea ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 57 South Korea ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 58 South Korea ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 59 Latin America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 60 Latin America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 61 Latin America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 62 Latin America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 63 Brazil ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 64 Brazil ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 65 Brazil ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 66 Mexico ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 67 Mexico ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 68 Mexico ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 69 Argentina ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 70 Argentina ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 71 Argentina ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 72 Middle East and Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 73 Middle East and Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 74 Middle East and Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 76 South Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 77 South Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 78 South Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 79 Saudi Arabia ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 80 Saudi Arabia ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 82 UAE ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 83 UAE ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 84 UAE ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 85 Kuwait ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 86 Kuwait ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 87 Kuwait ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Ovarian cancer drugs: Market outlook
Fig. 9 Ovarian cancer drugs: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Ovarian cancer drugs market driver impact
Fig. 15 Ovarian cancer drugs market restraint impact
Fig. 16 Ovarian cancer drugs market strategic initiatives analysis
Fig. 17 Ovarian cancer drugs market: Therapeutic Class movement analysis
Fig. 18 Ovarian cancer drugs market: Therapeutic Class outlook and key takeaways
Fig. 19 PARP inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Angiogenesis inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 PD-L1 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Ovarian cancer drugs market: Treatment movement analysis
Fig. 23 Ovarian cancer drugs market: Treatment outlook and key takeaways
Fig. 24 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Ovarian cancer drugs market: End-use movement analysis
Fig. 28 Ovarian cancer drugs market: End-use outlook and key takeaways
Fig. 29 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Targeted therapy & others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Global ovarian cancer drugs market: Regional movement analysis
Fig. 34 Global ovarian cancer drugs market: Regional outlook and key takeaways
Fig. 35 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Treatment, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Description

Table of Contents

List of Tables

Ovarian Cancer Drugs Market Growth & Trends:

Ovarian Cancer Drugs Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Ovarian Cancer Drugs Market Variables, Trends & Scope

Chapter 4. Ovarian Cancer Drugs: Therapeutic Class Estimates & Trend Analysis

Chapter 5. Ovarian Cancer Drugs: End-use Estimates & Trend Analysis

Chapter 6. Ovarian Cancer Drugs: Treatment Estimates & Trend Analysis

Chapter 7. Ovarian Cancer Drugs Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures